In the swiftly evolving field of immuno-oncology, T-cell redirecting bispecific antibodies (TRBAs), a type of antibody that can bind to two different antigens simultaneously, are a newly emerging platform in immunotherapy for cancer.1 To date, only the BiTE®, (bispecific T-cell engager) molecule blinatumomab has received U.S. FDA approval for a hematological cancer. More than 50 bispecific antibodies are currently in clinical trials.
Like CAR T-cells, TRBAs are engineered to specifically target tumor-associated antigens on the surface of cancer cells. However, currently approved autologous CAR T-cell therapies require taking blood from the cancer patient, processing their white cells, engineering them to attack the patient's specific cancer, and reinfusing the CAR T-cells into the patient where they grow and kill the cancer. By contrast, the bispecific antibody technology that is currently FDA-approved is “off-the-shelf” and requires no ex vivo manipulation. Thus, TRBAs may be viewed as simpler and faster to produce cellular anti-cancer immunotherapy.
This webinar is part of the Preparing Community Providers for Bispecific Antibodies education project.
Funding & support provided by Amgen.